3I/ATLAS Interstellar Comet or Alien Spacecraft? Here's complete truth
Interstellar Comet
or Alien Spacecraft?
Let's find out. In July 2025, astronomers identified a new object passing through the solar system. Named 3I/ATLAS, this interstellar object became the subject of global attention. While it is officially classified as a comet, one team of researchers has introduced a controversial idea: Could it be an alien spacecraft? The debate raises questions about what we know about space and what may lie beyond.
3I/ATLAS NASA Statement
3I/ATLAS
was first observed in July 2025 by a telescope in Chile that is part of NASA's Asteroid Terrestrial-impact Last Alert System (ATLAS). The telescope initially detected what appeared to be an unknown asteroid. The discovery was reported to the Minor Planet Center.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Artificial Intelligence
MBA
Technology
Degree
others
Finance
Leadership
CXO
Digital Marketing
Cybersecurity
Product Management
Data Science
Healthcare
MCA
Project Management
Public Policy
Data Analytics
Design Thinking
Others
healthcare
PGDM
Data Science
Management
Operations Management
Skills you'll gain:
Duration:
7 Months
S P Jain Institute of Management and Research
CERT-SPJIMR Exec Cert Prog in AI for Biz India
Starts on
undefined
Get Details
Follow-up observations confirmed the object was a comet, later named 3I/ATLAS. Scientists established that it had interstellar origins, making it the third known object to enter the solar system from beyond.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Play War Thunder now for free
War Thunder
Play Now
Undo
Also Read:
Denise Richards Aaron Phypers Ugly Court Battle: Star accuses estranged husband of… Here's what she said
3I/ATLAS Interstellar Comet or Alien Spacecraft?
NASA estimates that 3I/ATLAS is more than 12 miles wide. It is traveling at 37 miles per second relative to the Sun. On October 30, 2025, it will come within about 130 million miles of Earth.
Live Events
Most scientists agree that 3I/ATLAS has the features of a typical icy comet. These include a trajectory and speed consistent with other known interstellar objects.
Harvard Astrophysicist Avi Loeb Proposes Alien Technology Theory
Harvard astrophysicist
Avi Loeb and two other researchers recently released a paper suggesting an alternate possibility. Published on July 16, 2025, on the preprint server arXiv, the paper questions whether 3I/ATLAS could be alien technology.
Loeb is known for encouraging scientists to consider extraterrestrial explanations. He co-founded the Galileo Project, which focuses on scientifically searching for alien artifacts.
In a blog post, Loeb described the paper as a 'pedagogical exercise.' He explained that it explores the unusual trajectory of the object and does not claim a definitive conclusion. He also noted that the hypothesis suggests that intelligent civilizations might avoid detection to protect themselves from cosmic threats.
3I/ATLAS Interstellar Comet or Alien Spacecraft? Scientific Community Responds with Skepticism
Many experts have dismissed the theory. Chris Lintott, an Oxford University astronomer involved in tracing 3I/ATLAS's origin, called the alien theory 'nonsense' in a statement to Live Science. He emphasized that it distracts from ongoing research.
Loeb himself admitted that the object is most likely a natural comet. However, he believes that exploring different possibilities can lead to scientific discovery.
Also Read:
Leagues Cup 2025 New Format Explained: Start, end date, teams, structure, grouping, rules, points system, ranking, tickets, how to watch and stream online
Avi Loeb's Previous Claims About Interstellar Objects
This is not the first time Loeb has made such claims. In 2017, he suggested that the interstellar object
Oumuamua
could be alien technology. The object had a strange shape and accelerated near the Sun. Loeb proposed that it moved like a light sail, a method that could be used by intelligent beings.
In 2023, Loeb recovered fragments from a meteor labeled IM1 that struck Earth in 2014. He claimed the metallic spherules found off Papua New Guinea were interstellar and unmatched by known solar system alloys. The origin—natural or artificial—remains unclear.
Interstellar Visitors in Past
Before 3I/ATLAS, only two other interstellar objects had been confirmed. Oumuamua was detected in 2017. Comet Borisov passed through in 2019. Both sparked discussions among scientists about what they could tell us about other star systems.
FAQs
What is 3I/ATLAS and why is it important?
3I/ATLAS is an interstellar comet observed in 2025. It is only the third known object to enter our solar system from beyond, raising questions about cosmic activity.
Did scientists confirm 3I/ATLAS is an alien spacecraft?
No. Most scientists believe it is a comet. One theory by
Avi Loeb
explores the idea of alien origin but is not backed by evidence or peer-reviewed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
29 minutes ago
- Economic Times
Seeds of seabuckthorn, Himalayan buckwheat part of experiment on ISS
Reuters NASA's SpaceX Crew-11 crew members (File photo) Seeds of seabuckthorn and buckwheat grown in the cold desert of Ladakh are part of the experiments on board the International Space Station flown by NASA's Crew-11 mission. Seeds procured from 11 nations across five continents are part of the study spearheaded by US-based bioastronautics firm Jaguar Space, which plans to expose the seeds to microgravity conditions for a week. The seeds are part of the "Emerging Space Nation's Space for Agriculture & Agriculture for Space" payload that flew to the ISS along with NASA's Crew-11, which lifted off from Florida on Friday and docked onto the orbital lab on seeds will be brought back by the Crew-10, which is expected to return to Earth later this month. The seeds grown in Ladakh were sourced by Bengaluru-based space start-up Protoplanet. "We will study how the seeds react to micro-gravity conditions and their potential use as a food source for long-duration space missions," Siddharth Pandey, Director, Protoplanet, told stated that Protoplanet has contributed sea buckthorn and Himalayan tartary, nutrient-rich plants native to high-altitude regions. The Himalayan tartary is a variety of buckwheat that is nutrient-rich and return from space, the seeds will be studied by Indian to Jaguar Space, the World Seeds study examines how seeds react to the unique stresses of the space environment before they begin to grow, focusing on fundamental processes such as the activation of genes and metabolic pathways essential for germination. This experiment explores the potential of previously unexamined species to contribute to future space agriculture initiatives. Seeds from the Maldives, Argentina, Brazil, Costa Rica, Guatemala, Nigeria, Armenia, Egypt, Pakistan and Nigeria are part of the experiment. "Beyond its scientific potential to advance research on climate resilience and global food security, the World Seeds payload represents a meaningful step toward ensuring that, as humanity becomes a spacefaring civilization, the millennia-old knowledge, biodiversity, and cultural heritage of communities around the world are carried forward as an essential part of that journey," said Dr Luis Zea, Founder of Jaguar Space.
Deccan Herald
43 minutes ago
- Deccan Herald
Seeds of seabuckthorn, Himalayan buckwheat part of experiment on ISS
The seeds are part of the 'Emerging Space Nation's Space for Agriculture & Agriculture for Space' payload that flew to the ISS along with NASA's Crew-11.
Time of India
an hour ago
- Time of India
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions . Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity CXO others Public Policy Healthcare Digital Marketing Degree MBA Artificial Intelligence Others PGDM Data Science Data Analytics Product Management MCA Operations Management Leadership Design Thinking Project Management Finance Management healthcare Technology Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details Q. What are melanoma cells by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. Live Events This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites. Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine? A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines. The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding. According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program. Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
